NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
NetraMark Holdings (OTCQB: AINMF) has announced a strategic collaboration to advance glioblastoma (GBM) research using its NetraAI platform. The company has secured access to clinical and biomarker datasets from a leading U.S. academic medical center to develop therapeutic decision support tools for future GBM trials.
The collaboration will analyze longitudinal cerebrospinal fluid (CSF) proteomic datasets through six key objectives, including distinguishing GBM samples, differentiating tumor types, and studying disease recurrence patterns. The project aims to address the challenges in GBM treatment, where clinical trials face a 90% failure rate and patients have a median survival of just 15 months.
NetraMark Holdings (OTCQB: AINMF) ha annunciato una collaborazione strategica per avanzare la ricerca sul glioblastoma (GBM) utilizzando la sua piattaforma NetraAI. L'azienda ha ottenuto l'accesso a set di dati clinici e biomarcatori da un prestigioso centro medico accademico statunitense per sviluppare strumenti di supporto alle decisioni terapeutiche per futuri trial sul GBM.
La collaborazione analizzerà set di dati proteomici longitudinali del liquido cerebrospinale (CSF) attraverso sei obiettivi chiave, tra cui distinguere campioni di GBM, distinguere i tipi di tumore e studiare i pattern di recidiva della malattia. Il progetto mira ad affrontare le sfide nel trattamento del GBM, dove i trial clinici hanno un tasso di fallimento del 90% e i pazienti hanno una sopravvivenza mediana di soli 15 mesi.
NetraMark Holdings (OTCQB: AINMF) ha anunciado una colaboración estratégica para avanzar en la investigación del glioblastoma (GBM) utilizando su plataforma NetraAI. La empresa ha asegurado el acceso a conjuntos de datos clínicos y de biomarcadores de un destacado centro médico académico estadounidense para desarrollar herramientas de apoyo a decisiones terapéuticas para futuros ensayos de GBM.
La colaboración analizará conjuntos de datos proteómicos longitudinales del líquido cefalorraquídeo (CSF) a través de seis objetivos clave, incluyendo distinguir muestras de GBM, diferenciar tipos de tumores y estudiar patrones de recurrencia de la enfermedad. El proyecto tiene como objetivo abordar los desafíos del tratamiento del GBM, donde los ensayos clínicos enfrentan una tasa de fracaso del 90% y los pacientes tienen una supervivencia media de apenas 15 meses.
NetraMark Holdings (OTCQB: AINMF)가 NetraAI 플랫폼을 활용한 교모세포종(GBM) 연구를 진전시키기 위한 전략적 협업을 발표했습니다. 이 회사는 미래 GBM 시험을 위한 치료 의사결정 지원 도구를 개발하기 위해 미국의 선도적인 학술 의과원으로부터 임상 및 바이오마커 데이터 세트에 접근할 수 있도록 확보했습니다.
협업은 척수액(CSF) 프로테오믹 데이터세트를 6가지 주요 목표를 통해 분석할 것이며, 여기에는 GBM 샘플 구분, 종양 유형 차별화, 질병 재발 패턴 연구 등이 포함됩니다. 이 프로젝트는 임상 시험의 90% 실패율과 환자의 중앙 생존 기간이 단 15개월에 불과한 GBM 치료의 도전을 해결하는 것을 목표로 합니다.
NetraMark Holdings (OTCQB: AINMF) a annoncé une collaboration stratégique pour faire progresser la recherche sur le glioblastome (GBM) en utilisant sa plateforme NetraAI. L'entreprise a obtenu l'accès à des ensembles de données cliniques et de biomarqueurs d'un important centre médical académique américain pour développer des outils d'aide à la décision thérapeutique pour de futurs essais GBM.
La collaboration analysera des ensembles de données protéomiques longitudinales du liquide céphalo-rachidien (CSF) selon six objectifs clés, notamment distinguer les échantillons GBM, différencier les types de tumeurs et étudier les motifs de récurrence de la maladie. Le projet vise à relever les défis du traitement du GBM, où les essais cliniques présentent un taux d'échec de 90% et les patients ont une survie médiane de seulement 15 mois.
NetraMark Holdings (OTCQB: AINMF) hat eine strategische Zusammenarbeit angekündigt, um die Glioblastom-Forschung (GBM) mit ihrer NetraAI-Plattform voranzutreiben. Das Unternehmen hat Zugriff auf klinische und Biomarker-Datensätze von einem führenden US-amerikanischen akademischen Medizinzentrum gesichert, um therapeutische Entscheidungsunterstützungstools für zukünftige GBM-Studien zu entwickeln.
Die Zusammenarbeit wird longitudinale proteomische Datensätze aus dem Liquor cerebrospinalis (CSF) durch sechs Hauptziele analysieren, darunter die Unterscheidung von GBM-Proben, die Unterscheidung von Tumortypen und die Untersuchung von Krankheitsrezidivmustern. Das Projekt zielt darauf ab, die Herausforderungen in der GBM-Behandlung anzugehen, bei der klinische Studien eine Ausfallrate von 90% haben und Patienten eine mittlere Überlebenszeit von nur 15 Monaten.
NetraMark Holdings (OTCQB: AINMF) عن تعاون استراتيجي لتعزيز أبحاث الورم الأرومي الدبقي/GBM باستخدام منصتها NetraAI. الشركة نجحت في الحصول على وصول إلى مجموعات البيانات السريرية وبيوماتريكس من مركز طبي أكاديمي رائد في الولايات المتحدة لتطوير أدوات دعم قرارات العلاج للتجارب المستقبلية لـ GBM.
سيقوم التعاون بتحليل مجموعات بيانات بروتينات السائل الدماغي النخاعي (CSF) الطولية من خلال ستة أهداف رئيسية، بما في ذلك التمييز بين عينات GBM، وتمييز أنواع الأورام، ودراسة أنماط تكرار المرض. يهدف المشروع إلى معالجة التحديات في علاج GBM، حيث تواجه التجارب السريرية معدل فشل يصل إلى 90٪ ويمتلك المرضى بقاءً وسطياً قدره فقط 15 شهراً.
NetraMark Holdings (OTCQB: AINMF) 宣布与合作伙伴建立战略合作，以利用其 NetraAI 平台推动胶质母细胞瘤（GBM）研究。该公司已获得美国领先的学术医学院中心的临床和生物标志物数据集，以开发未来 GBM 临床试验的治疗决策支持工具。
该合作将通过六个关键目标分析纵向的脑脊液（CSF）蛋白组数据集，包括区分 GBM 样本、区分肿瘤类型以及研究疾病复发模式。该项目旨在解决 GBM 治疗中的挑战，其中临床试验的失败率高达 90%，患者中位生存期只有 15 个月。
- Access to proprietary clinical and biomarker datasets from a leading U.S. academic medical center
- Application of NetraAI platform to identify patient subgroups and optimize trial enrichment strategies
- Comprehensive analysis approach covering six distinct research objectives in GBM treatment
- Potential to improve clinical trial success rates in a field with 90% failure rate
- Complex research project with no guaranteed success in improving trial outcomes
- Challenging disease area with historically poor patient outcomes (15-month median survival)
- Multiple variables and complex data analysis required for meaningful results
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a new collaboration focused on glioblastoma (GBM) research. The collaboration, supported by a license to proprietary know-how, grants NetraMark access to clinical and biomarker datasets from a leading U.S. academic medical center.
NetraAI, the Company’s explainable AI platform, will be applied to these datasets to identify patient subgroups to help build a therapeutic decision support tool that can be used to inform future GBM trials.
Glioblastoma is an aggressive and difficult-to-treat cancer, with median survival of just 15 months and fewer than
Project Objectives
NetraMark’s analysis under the collaboration will focus on generating novel insights and hypotheses from longitudinal cerebrospinal fluid (CSF) proteomic datasets. NetraAI will analyze the data into explainable and unexplainable subpopulations, seeking to deliver insights in the form of NetraPersonas—collections of patients, variables, and statistical evidence that can be leveraged to optimize future trial enrichment strategies.
The specific objectives include:
- Glioma vs. Non-Tumor Controls – Identify markers distinguishing GBM samples
- Glioma vs. Non-Glioma Brain Tumors – Differentiate GBM from supratentorial brain metastases to refine glioma-specific biomarkers.
- Disease Recurrence – Contrast primary and recurrent gliomas to identify molecular markers of recurrence and tumor evolution.
- Impact of Resection – Evaluate paired pre- and post-surgical resection samples to understand molecular changes from surgery.
- Impact of Chemoradiation – Analyze paired pre- and post-treatment samples to assess therapy response and resistance mechanisms.
- Impact of Immunotherapy – Explore pre- and post-immunotherapy lumbar CSF samples to identify molecular effects of immunotherapy.
Data and Resources
The academic partner will provide expanded longitudinal glioblastoma proteomic datasets generated on the SomaLogic platform, along with related de-identified materials.
This collaboration represents an important opportunity in applying explainable AI to a significant challenge in oncology, with the potential to help trial sponsors design more efficient, targeted, and successful glioblastoma studies.
“We are excited to collaborate with a leading academic medical center on this challenging area of oncology,” said Josh Spiegel, President of NetraMark. “By applying NetraAI to high-quality glioblastoma datasets, we aim to identify explainable patient subgroups that can guide treatment strategies, accelerate biomarker discovery, and support the design of more successful clinical trials.”
About NetraAI
In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.
About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the Company's primary objectives under the Collaboration Agreement to evaluate data which aims to provide oncologists with tools to identify biologically meaningful GBM subgroups that may respond differently to investigational therapies and potentially help trial sponsors design more efficient, targeted, and successful glioblastoma studies, which are based on NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Contact Information:
Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549
FAQ
What is the purpose of NetraMark's (AINMF) collaboration in glioblastoma research?
What are the main objectives of NetraMark's glioblastoma research project?
What is the current success rate of glioblastoma clinical trials?
What is the survival rate for glioblastoma patients?
How will NetraMark analyze the glioblastoma data?
